Výsledky vyhledávání

FEIBA in the treatment of acquired haemophilia A: Results from the prospective multicentre French ‘ FEIBA dans l'hémophilie A acquise’ ( FEIBHAC ) registry

Autor: J. Y. Borg, A.-M. Masquelier, I Durieu, E. Dolimier, C Négrier, Hervé Levesque

Publikováno v: Haemophilia. 21:330-337

Summary Factor VIII inhibitor bypass activity (FEIBA) is a recommended first-line bypassing agent for bleeding episodes in patients with acquired haemophilia A (AHA). Due to the low incidence of AHA, available clinical data on FEIBA treatment are lim

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcff939bd41a2975c6fcd15f349ec4ae
https://doi.org/10.1111/hae.12574

Zobrazit plný text záznamu

Outcome of acquired haemophilia in France: the prospective SACHA (Surveillance des Auto antiCorps au cours de l'Hémophilie Acquise) registry

Autor: J Y, Borg, B, Guillet, V, Le Cam-Duchez, J, Goudemand, H, Lévesque, Bordessoule

Publikováno v: Haemophilia. 19:564-570

Although extremely rare, acquired haemophilia A (AHA) can cause severe bleeding, which may be fatal. The underlying causes of autoantibody development are not fully understood. Treatment goals are bleeding control and autoantibody eradication. At the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f10b6c23c4592143f29c824d93232fd
https://doi.org/10.1111/hae.12138

Zobrazit plný text záznamu

Post-authorization safety study of Clottafact

Autor: C, Négrier, C, Rothschild, J-Y, Borg, T, Lambert, S, Claeyssens, L, Sanhes, N, Stieltjes, A, Bertrand, M-H, André, P, Sié, Y, Gruel, Z, Tellier

Publikováno v: Vox sanguinis. 111(4)

A new fibrinogen concentrate ClottafactThe analysis was descriptive and performed on 3 subgroups: prophylaxis vs. on-demand treatment, age (6,12 and ≥12) and severity of the deficiency.Fourteen patients [1-78 years] were included in 7 centres and f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::7e0cd3720d73fbf5bea50b3caf855c62
https://pubmed.ncbi.nlm.nih.gov/27583698

Zobrazit plný text záznamu

Utilisation quotidienne du facteur VII activé recombinant dans les saignements aigus de l’hémophile acquise A : résultats d’ACQUI-7, une étude française prospective

Autor: A. Borel-Derlon, J. Y. Borg, Hervé Levesque, Achille Aouba, Jean-François Schved, B. Villette, H. Schneid, Benoît Guillet

Publikováno v: La Revue de Médecine Interne. 37:A191-A192

Introduction L’efficacite et la tolerance du facteur VII active recombinant (rFVIIa) sont reconnues chez les patients avec une hemophilie A acquise (HAA), mais des donnees detaillees sur le controle du saignement en pratique medicale sont limitees.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::21a554b3065bbf75267ff2c982b01c3f
https://doi.org/10.1016/j.revmed.2016.10.236

Zobrazit plný text záznamu

Factor XI replacement for inherited factor XI deficiency in routine clinical practice: results of the HEMOLEVEN prospective 3-year postmarketing study

Autor: C. Boyer-Neumann, F. Bauduer, E. de Raucourt, Marc Trossaert, Jocelyne Peynet, F. Bridey, Jenny Goudemand, J.-Y. Borg, Céline Henriet, A. Faradji, Pierre Chamouni, C. Chatelanaz, Philippe Beurrier

Publikováno v: Haemophilia

Summary Factor XI (FXI)-deficient patients may develop excessive bleeding after trauma or surgery. Replacement therapy should be considered in high-risk situations, especially when FXI levels are below 20 IU dL−1. HEMOLEVEN is a human plasma-derive

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d9be918d42315ff931f414f2e1ffc86
https://pubmed.ncbi.nlm.nih.gov/25817556

Zobrazit plný text záznamu

Plný text ve formátu HTML

Antiphospholipid Antibodies in the Acute Phase of Cerebral Ischaemia in Young Adults: A Descriptive Study of 139 Patients

Autor: B. Mihout, J Y Borg, A Blohorn, Onnient Y, A Triquenot, E. Guegan-Massardier, F Tron

Publikováno v: Cerebrovascular Diseases. 13:156-162

A total of 139 young stroke patients were consecutively examined and tested for antiphospholipid antibodies (APLA) to evaluate the role of these antibodies in cerebral ischaemia before the age of 45. APLA were found in 28.8% of patients. Two factors,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4eb82d18c8fdb5aed72fc1a268fbb3b5
https://doi.org/10.1159/000047769

Zobrazit plný text záznamu

Prothrombotic Inherited Abnormalities Other Than Factor V Leiden Mutation Do Not Play a Role in Venous Thrombosis in Inflammatory Bowel Disease

Autor: C, Guédon, V, Le Cam-Duchez, O, Lalaude, J F, Ménard, E, Lerebours, J Y, Borg

Publikováno v: American Journal of Gastroenterology. 96:1448-1454

Because the incidence of thromboembolism is increased in patients with inflammatory bowel disease, we attempted to assess the role of prothrombotic inherited coagulation abnormalities in the development of thrombosis.Four populations were compared: 1

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3546a005c58ea8283fa7f2019f49b8c
https://doi.org/10.1111/j.1572-0241.2001.03797.x

Zobrazit plný text záznamu

The IgG autoimmune response in postpartum acquired hemophilia A targets mainly the A1a1 domain of FVIII

Autor: Géraldine Lavigne-Lissalde, J. Balicchi, Claude Granier, Caroline Pfeiffer, Hervé Levesque, Yves Gruel, Christopher Cayzac, Eve Mathieu-Dupas, Priscilla Lapalud, T. Ali, Jean-François Schved, J. Y. Borg

Publikováno v: Journal of thrombosis and haemostasis : JTH. 10(9)

Summary. Background: Acquired hemophilia A (AHA) is a severe life-threatening autoimmune disease due to the development of autoantibodies that neutralize the procoagulant activity of factor VIII (FVIII). In rare cases, AHA occurs in the postpartum pe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0f5e7d31434b9ccbddacbdbb0ba5329
https://pubmed.ncbi.nlm.nih.gov/22784315

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání